Topic:

M&A

Latest Headlines

Latest Headlines

Trial tech outfit Clinical Ink merges with app upstart

Clinical Ink, a provider of trial data software, is merging with Boston's CentrosHealth in hopes of expanding its platform for paperless studies.

Kite Pharma adds manufacturing assets with T-Cell Factory acquisition

Biotech Kite Pharma, which has become a force in cancer immunotherapy, has added some more manufacturing capabilities to the operations it has been beefing up.

Retrophin bags rare disease approval, FDA voucher in $75M deal

Orphan drug biotech Retrophin is the new owner of an FDA-approved rare disease treatment and a potentially lucrative voucher for a future speedy review thanks to a $75 million buyout agreement.

Endo's shown it's willing to spend. But with Salix gone, what's left worth buying?

As Endo showed last week with its failed $10 billion bid for North Carolina's Salix, it's willing to shell out some serious dough if the right target comes along. The question is, what's left?

CAR-T player Kite Pharma buys its way into Europe and pads its anticancer arsenal

Kite Pharma, a leader among companies in the fast-moving field of cancer immunotherapy, is expanding its arsenal of potential treatments and making European landfall with a biotech buyout.

All clear for Actavis to become Allergan as EU watchdogs approve $66B merger

Actavis and Allergan can finally celebrate: They've cleared the last hurdle to closing their $66 billion merger agreement.

Pfizer chief gets a pay boost, but two underlings get bigger ones

Pfizer CEO Ian Read got a nice pay bump for 2015, with a total package of $23.3 million--more than one-quarter bigger than the previous year's total. But a big chunk of that increase came in the value of his pension. Back that out, and Read's compensation only grew by $280,000.

Teva buy Mylan? It's not happening, BMO analyst says

Heard the Teva-Mylan takeover rumors? Forget them, one analyst says.

Pulmatrix backs its way onto Wall Street with merger deal

Respiratory biotech Pulmatrix is taking an end-around path to the public market, signing a deal to merge with tiny Ruthigen to better fund its pipeline of inhalable treatments.

UPDATED: Sorry, Endo. Valeant's back on top with $173-per-share Salix bid

So you thought you could wrestle Salix away from Valeant, Endo? The Canadian pharma has a message for you: Think again.